Unexpected worsening of doxorubicin cardiotoxicity upon intermittent fasting

Med. 2023 May 12;4(5):288-289. doi: 10.1016/j.medj.2023.04.005.

Abstract

Recently in Cell Metabolism, Ozcan et al. used preclinical and clinical data to suggest that alternate-day fasting may exacerbate the cardiotoxic effects of doxorubicin through the TFEB/GDF15 pathway, leading to myocardial atrophy and impaired cardiac function. The link between caloric intake, chemotherapy-induced cachexia, and cardiotoxicity warrants more clinical attention.

Keywords: alternate-day fasting; cardiotoxicity; doxorubicin; intermittent fasting.

Publication types

  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Cardiotoxicity* / etiology
  • Cardiotoxicity* / metabolism
  • Doxorubicin / adverse effects
  • Doxorubicin / metabolism
  • Fasting
  • Humans
  • Intermittent Fasting
  • Myocytes, Cardiac* / metabolism

Substances

  • Doxorubicin